Skip to content

Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use

A Prospective Randomized Controlled Trial of Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06719180
Enrollment
100
Registered
2024-12-05
Start date
2024-12-01
Completion date
2025-10-31
Last updated
2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysterectomy, Post Operative Analgesia

Brief summary

The purpose of this study is to determine whether an injection of a local anesthetic (Bupivacaine with epinephrine) in the vaginal cuff prior to closure would result in less immediate postoperative pain medication and increase patient comfort/satisfaction.

Interventions

DRUGBupivacain

Injection into the vaginal cuff will occur before vaginal cuff closure with stratafix suture. There will be four points of injection 1cm from the edges of the vaginal cuff with a sterilized needle to a depth of 3-4cm. 5cc of bupivacaine with epinephrine or 5cc of normal saline will be injected into each area

OTHERSaline (NaCl 0,9 %) (placebo)

A saline placebo

Sponsors

MediSys Health Network
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients 18 years and older requiring total laparoscopic hysterectomy with or without bilateral salpingo-oophorectomy for benign conditions * Presence of malignancy

Exclusion criteria

* Conversion to laparotomy * Previous multiple abdominal and/or pelvic surgeries * Significant medical comorbidities or cardiac history * Poor initial Aldrete score4 (\<10) * Significant pre-op pain medication use * Contraindication to any medication that would be used in the study (Bupivacaine, epinephrine, tramadol or oxycodone)

Design outcomes

Primary

MeasureTime frame
Milligrams of Morphine Equivalent UsedFrom enrollment to end of treatment at 4 hours.

Secondary

MeasureTime frameDescription
Counts of Non-Opioid Analgesics UsedFrom enrollment to end of treatment at 4 hours.
Patient Change in Pain Score (0-10)From Baseline to end of treatment at 4 hoursChange in value of pain score, measured on a 0-10 scale.

Countries

United States

Contacts

Primary ContactHosam Hanna, MD
hhanna@jhmc.org(718) 670-5571

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026